主持人观点:IgA肾病的治疗——与不确定性共处
本文是对Pozzi与Rauen等关于STOP-IgAN试验解读的评论。文章强调在持续蛋白尿>0.75 g/天的高危患者中严格应用滴定式RAS抑制的重要性,同时指出该试验在随访时长、患者分层和给药方案等方面带来不确定性,认为仍需更多试验以明确激素单药或联合免疫抑制治疗的价值。
要点
- STOP-IgAN试验强化了对持续蛋白尿>0.75 g/天的高危IgA肾病患者严格应用滴定式RAS抑制的认识。
- 该试验对激素单药或激素联合免疫抑制治疗在RAS抑制失败患者中的总体价值与风险提出了新的不确定性。
- 不确定性涉及研究设计中的随访时长、参与者分层(尤其是基础病理)和给药方案等问题。
核心结论
- STOP-IgAN试验对特定IgA肾病患者使用激素单药或激素联合免疫抑制治疗的获益提出关键关切,但并未否定高危IgA肾病患者使用激素单药治疗的效用,同时进一步降低了激素联合免疫抑制(至少是序贯环磷酰胺和硫唑嘌呤方案)的价值。
研究设计与样本
- 本文为针对Pozzi与Rauen等关于STOP-IgAN试验解读的评论文章。
主要发现
- 该评论阐明了STOP-IgAN这项里程碑式随机试验的潜在优势与弱点。
- 文章强调在持续蛋白尿>0.75 g/天的高危患者中严格应用滴定式RAS抑制的重要性。
- 文章指出该试验在激素单药或激素联合免疫抑制治疗方面带来新的不确定性,涉及随访时长、参与者分层(尤其是基础病理)和给药方案等问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文提及的不确定性涉及研究设计中的随访时长、参与者分层(尤其是基础病理)和给药方案等问题。
- 原文希望更多试验、更好的患者选择方法、改进的替代终点和更安全的方案能减少最佳治疗实践的不确定性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A Polar Views discussion by Pozzi and Rauen et al. on the interpretation and clinical application of the recently published Supportive Versus Immunosuppressive Therapy of Progressive IgA Nephropathy (STOP-IgAN) trial has elucidated important points concerning potential strengths and weaknesses of this landmark randomized trial. This critical examination of the impact of steroid monotherapy or steroid plus an immunosuppressive (IS) agent compared with 'supportive' therapy with inhibitors of the renin-angiotensin system (RAS) has enhanced our appreciation of the importance of rigorous application of titrated RAS inhibition in high-risk patients with persistent proteinuria >0.75 g/day. At the same time, it brings a new level of uncertainty concerning the overall value and risk of steroid or steroid plus IS therapy in patients failing such 'supportive' therapy. Some of these uncertainties revolve on issues of study design, such as the duration of follow-up, participant stratification (particularly underlying pathology) and dosing regimens. It is hoped that additional trials, better methods of patient selection, improved surrogate end points and safer regimens will lead to less uncertainty over the best treatment practices. On balance, the STOP-IgAN trial raises some key concerns about the merits of steroid alone or steroid plus IS therapy for selected subjects with IgAN, but it does not by itself close the door on the utility of steroid monotherapy in subjects with high-risk IgAN, even as it further degrades the value of steroid plus IS, at least with sequential cyclophosphamide and azathioprine.
引用
- Glassock RJ. Moderator's view: Treatment of IgA nephropathy-getting comfortable with uncertainty. Nephrol Dial Transplant. 2016. PMID: 27515695
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。